DareVita has surfaced in business press with a product framing that should immediately trigger scrutiny from anyone fluent in performance neuroscience: a "24-hour system for supporting human performance." The Business Journals carried the announcement, but no mechanism, dosing protocol, or outcome data has been disclosed in available reporting. That evidentiary gap is the actual headline.
What "24-hour" actually denotes is undefined. It could mean continuous-wear delivery, circadian-aligned dosing windows, or a brand cadence claim. Without a published ingredient stack, bioavailability profile, or third-party measurement of cognitive endpoints — reaction time, working-memory load, sleep latency, HPA-axis modulation — the system sits in the same empirical vacuum as most daily-stack launches in the longevity category.
The disclosed-evidence gap
For a product positioned around human performance, the absence of specific endpoints is the finding worth reporting. Any clinical reader should ask:
- What physiological variable does TREO modulate — cortisol, cerebral blood flow, neurotransmitter turnover?
- Is the 24-hour window a pharmacokinetic half-life, a behavioral protocol, or a marketing construct?
- Where is the pre-registration of any human-trial protocol with effect-size reporting?
Until those answers appear, the claim is functionally indistinguishable from an expectation-effect framing. Subjective energy ratings move under such framings on their own. That is not a neuroplasticity story.
Parallel signal: Ellis's 90-day men's longevity system
In the same news cycle, Digital Journal covered a structurally different launch — Dr. John Spencer Ellis's 90-day, 12-session coaching program for men over 40, announced June 27, 2026, out of Las Vegas. The contrast is instructive.
Ellis's program names specific intervention domains: hormonal optimization, sleep architecture restoration, body composition and lean muscle development, inflammation management, cognitive performance, posture and physical presence, nutrition strategy, and what the announcement terms "mindset architecture." Delivery is supervised and behavioral, not a single ingestible product. That structure gives the program a falsifiable framework — each domain is independently measurable, and the 90-day window is long enough to capture non-acute adaptation rather than transient stimulation.
The integration claim matters more than the 30-year practitioner credential. Ellis positions aesthetics and longevity as two expressions of the same upstream biology rather than separate verticals — a framing consistent with current literature on inflammaging, sarcopenic trajectories, and androgen decline in males 40+.
What to verify before committing
A "24-hour" label is a marketing position. Cognitive performance is a multi-week, multi-system outcome. The most expensive error in the supplement-coaching hybrid market is confusing those two timescales. Before spending on any system in this category, demand:
- A complete ingredient list with milligram amounts — no proprietary blends
- Third-party assay verification (USP, NSF, or equivalent)
- Any human-subject data with effect-size reporting, not just p-values
- A clear separation between acute subjective effects and durable structural change
TREO may eventually publish those data. Until it does, treat the 24-hour framing as a hypothesis, not a protocol.